expression, while HSF4 is a negative regulator. HSF1, HSF2 and HSF4 play a role in transcriptional control of other heat shock proteins. The various HSF proteins share about 40% sequence identity.

[0006] HSF1 activity has been implicated in several diseases, including cancer, and autoimmune, and viral diseases. HSF1 and other heat shock proteins (whose expression is increased by HSF1) are over-expressed in, or have otherwise been implicated in, breast, endometrial, fibrosarcoma, gastric, kidney, liver, lung, lymphoma, neuroectodermal, neuroblastoma, Ewing's sarcoma, prostate, skin, squamous cell, and testicular cancers, leukemia (e.g., promyelocytic leukemia), and Hodgkin's disease.

[0007] Accordingly, there is need for pharmacologically active agents that are capable of inhibiting HSF1. Such agents are potentially useful chemotherapeutic agents for the treatment of diseases or consditions in which HSF1 activity is mediated.

SUMMARY OF THE INVENTION

[0008] In one aspect, the present invention provides a compound, or a pharmaceutically acceptable salt or solvate thereof, as defined in claim 1.

[0009] In another aspect, the present invention provides a pharmaceutical composition which comprises a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable excipients.

[0010] In another aspect, the present invention provides a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition as defined herein, for use in therapy.

[0011] In another aspect, the present invention provides a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of cancer, autoimmune diseases or viral diseases.

[0012] In another example, the present invention provides a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a proliferative condition.

[0013] In another aspect, the present invention provides a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of cancer. In a particular embodiment, the cancer is a human cancer.

[0014] In another example, the present disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition as defined herein, for use in the production of a HSF1 inhibitory effect.

[0015] In another aspect, the present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for use in treatment of cancer, autoimmune diseases or viral diseases.

[0016] In another example, the present disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for use in the treatment of a proliferative condition.

[0017] In another example, the present disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for use in the treatment of cancer. Suitably, the medicament is for use in the treatment of human cancers.

[0018] In another example, the present disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for use in the production of a HSF1 inhibitory effect.

[0019] In another example, the present disclosure provides a method of inhibiting HSF1 *in vitro* or *in vivo*, said method comprising contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof.

[0020] In another example, the present disclosure provides a method of inhibiting cell proliferation *in vitro* or *in vivo*, said method comprising contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof.

[0021] In another example, the present disclosure provides a method of treating a HSF1-mediated condition or disease (for example, cancer, autoimmune diseases or viral diseases), in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition as defined herein.

[0022] In another example, the present disclosure provides a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound as defined

herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition as defined herein.

[0023] In another example, the present disclosure provides a method of treating cancer in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition as defined herein.

[0024] The present example further provides a method of synthesising a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof.

[0025] In another example, the present disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt or solvate thereof, obtainable by, or obtained by, or directly obtained by a method of synthesis as defined herein.

[0026] In another example, the present disclosure provides novel intermediates defined herein which are suitable for use in any one of the synthetic methods set out herein.

[0027] Preferred, suitable, and optional features of any one particular aspect of the present invention are also preferred, suitable, and optional features of any other aspect.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0028] Unless otherwise stated, the following terms used in the specification and claims have the following meanings set out below.

[0029] It is to be appreciated that references to "treating" or "treatment" include prophylaxis as well as the alleviation of established symptoms of a condition. "Treating" or "treatment" of a state, disorder or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, *i.e.*, arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, *i.e.*, causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.

[0030] A "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for

was removed *in vacuo*, a further portion of anhydrous DCM (2 ml) was added and then removed *in vacuo*. The resulting residue was re-dissolved in DCM (1 ml x 2) and added to a solution of Compound 214 (51 mg, 0.223 mmol) and pyridine (0.090 mL, 1.113 mmol) in anyhdrous DCM (2 ml). The reaction was left to stir for 19 h, then poured into sat. aq. $NaHCO_3$ aq. (20 mL) and the aqueous layer extracted with DCM (3 x 15 ml). The combined organic layer was washed with brine (15 ml), dried (Na_2SO_4) and concentrated *in vacuo* to afford the crude product as a green oil. Purification by biotage chromatography with a KP-NH column using a gradient of 0 to 100% EtOAc/cyclohexane afforded the required product as a green solid (45 mg, 51%). ^{1}H NMR (500 MHz, Chloroform-d) δ 12.10 (s, 1H), 8.78 (s, 1H), 8.42 (s, 1H), 8.18 – 8.07 (m, 3H), 7.39 (d, *J* = 8.4 Hz, 1H), 7.22 – 7.19 (m, 1H), 7.02 (d, *J* = 8.0 Hz, 1H), 3.61 (s, 2H), 2.81 (s, 3H), 2.40 (s, 6H). HRMS (ESI$^+$): calcd for $C_{20}H_{20}{}^{79}BrN_3O$ $(M + H)^+$, 398.0868; found 398.0858.

Preparation of Compound 216, N-(2-((dimethylamino)methyl)-5-((diphenylmethylene)amino)phenyl)-2-methylquinoline-6-carboxamide


[00298] Palladium acetate (2.42 mg, 0.011 mmol) was added to a suspension of Compound 215 (43 mg, 0.108 mmol), xantphos (12.49 mg, 0.022 mmol), cesium carbonate (70.4 mg, 0.216 mmol) and benzophenone imine (21.5 mg, 0.119 mmol) in anhydrous dioxane (1.2 ml). The reaction was degassed by 4 x vacuum/argon cycles and heated to 100 °C for 22 h. Further palladium(II) acetate (2.424 mg, 10.80 µmol) and xantphos (12.49 mg, 0.022 mmol) were added and the reaction allowed to heat at 100 °C for 24 h. The reaction was diluted with DCM (30 ml) and the solids were filtered off. The filtrate was washed with water (10 ml), brine (10 ml), dried Na_2SO_4 and concentrated *in vacuo*. Purification by biotage chromatography (KP-NH2 column) using a gradient of 8 to 100% EtOAc/cyclohexane gave the title compound as a pale yellow solid (16.5 mg, 31%). HRMS (ESI$^+$): calcd for $C_{33}H_{31}N_4O$ $(M + H)^+$, 499.2498; found 499.2492.

Example 165, *N*-(5-(2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-(dimethylamino)methyl)phenyl)-2-methylquinoline-6-carboxamide

[00299] To a stirring solution of Compound 216 (17 mg, 0.034 mmol) in THF (0.5 mL) at room temperature was slowly added 2M HCl aq. (0.043 mL, 0.085 mmol). The reaction was allowed to stir at room temperature for 2.25 h. The solvents were removed *in vacuo* and traces of water removed by co-evaporation with toluene. The resulting residue was then taken up in DCM/MeOH and dried (Na_2SO_4), filtered and concentrated again to afford N-(5-amino-2-((dimethylamino)methyl)phenyl)-2-methylquinoline-6-carboxamide. Oxalyl chloride (4.73 µL, 0.056 mmol) was added drop-wise to a solution of 1,4-benzodioxane carboxylic acid (8.89 mg, 0.049 mmol) and DMF (0.064 µL, 0.822

CLAIMS

1. A compound of formula I shown below:



I

wherein:

A_1 is selected from N or CR_1, A_2 is selected from N or CR_2, with the proviso that only one of A_1 or A_2 can be N;

R_1 and R_2 are each independently selected from hydrogen, fluoro, chloro, cyano, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;

R_4 is selected from fluoro, chloro, bromo, iodo, CF_3, OCF_3, cyano, NO_2, (1-4C)alkyl, (1-4C)alkoxy, or a group of the formula:

W-X-Y-Z

wherein

W is absent or (1-3C)alkylene;


X is -O- or -N(R^a)-, wherein R^a is selected from hydrogen or (1-2C)alkyl;

Y is absent or a (1-3C)alkylene;

Z is hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl;

and wherein any alkylene, alkyl or cycloalkyl group present in a R_4 substituent group is optionally further substituted by one or more substituent groups independently selected from halo, hydroxy, NR^bR^c, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy, and wherein R^b and R^c are each independently selected from hydrogen or (1-3C)alkyl;

Q is selected from a group of formula II:



II

wherein

A_{4a} and A_{4b} are each independently selected from N or CR_9, wherein each R_9 pesent is independently selected from hydrogen, halo, cyano, nitro, hydroxy,

NR^dR^e, (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl; wherein R^d and R^e are each independently selected from hydrogen or (1-3C)alkyl; and wherein any (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl group present in a R_9 substituent group is optionally substituted by one or more substiutents selected from halo, cyano, nitro, hydroxy, NR^fR^g or (1-3C)alkoxy, wherein R^f and R^g are each independently selected from hydrogen or (1-3C)alkyl;

A_{4c} is N or CR_{10};

R_{10} is selected from hydrogen, halo, amino, cyano, nitro, hydroxy or a group

$$W^1\text{-}X^1\text{-}Y^1\text{-}X^4\text{-}Z^1$$

wherein

W^1 is absent or a linker group of the formula $-[CR^hR^i]_p-$ in which p is an integer selected from 1, 2, 3 or 4, and R^h and R^i are each independently selected from hydrogen or (1-2C)alkyl;

X^1 is absent or -O-, -C(O)-, -C(O)O-, -OC(O)-, $-CH(OR^j)-$, $-N(R^j)-$, $-N(R^j)$-C(O)-, $-N(R^j)$-C(O)O-, -C(O)-$N(R^j)-$, $-N(R^j)C(O)N(R^j)-$, -S-, -SO-, $-SO_2-$, $-S(O)_2N(R^j)-$, or $-N(R^j)SO_2-$ wherein R^j is selected from hydrogen or methyl;

Y^1 is absent or a linker group of the formula $-[CR^kR^l]_q-$ in which q is an integer selected from 1, 2, 3 or 4, and R^k and R^l are each independently selected from hydrogen or (1-2C)alkyl;

X^4 is absent or -O-, -C(O)-, -C(O)O-, -OC(O)-, $-CH(OR^j)-$, $-N(R^j)-$, $-N(R^j)$-C(O)-, $-N(R^j)$-C(O)O-, -C(O)-$N(R^j)-$, $-N(R^j)C(O)N(R^j)-$, -S-, -SO-, $-SO_2-$, $-S(O)_2N(R^j)-$, or $-N(R^j)SO_2-$ wherein R^j is selected from hydrogen or methyl; and

Z^1 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl or heterocyclyl;


and wherein Z^1 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, NR^mR^n, (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-4C)alkanoyl, (1-4C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, $C(O)NR^mR^n$, $NR^mC(O)R^n$, $NR^mS(O)_2R^n$ and $S(O)_2NR^mR^n$; wherein R^m and R^n are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or R^m

and R^n can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z^1 is optionally further substituted by halo, cyano, nitro, hydroxy, carboxy, NR^oR^p, (1-2C)alkoxy, or (1-2C)alkyl; wherein R^o and R^p are selected from hydrogen or (1-2C)alkyl;

with the proviso that R_{10} is only hydrogen, halo or t-butyl when at least one of A_{4a} and A_{4b} is N or CR_9 in which R_9 is a substituent as defined above other than hydrogen;

or Q is a group of formula III:



III

wherein

A_5 is selected from N or CR_5, where R_5 is selected from hydrogen, halo, cyano, nitro, hydroxy, NR^qR^u, (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl; wherein R^q and R^u are each independently selected from hydrogen or (1-3C)alkyl, and wherein any (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteraryl, or 5 or 6 membered heterocyclyl group present in a R_5 substituent group is optionally substituted by one or more substitutents selected from halo, cyano, nitro, hydroxy, NR^vR^w, or (1-3C)alkoxy, wherein R^v and R^w are each independently selected from hydrogen or (1-3C)alkyl;

Ring A is:

a fused phenyl ring;

a fused 5 or 6 membered carbocyclic ring;

a fused 5 or 6 membered heteroaryl ring comprising one or two heteroatoms independently from N, S or O; or

a fused 5, 6 or 7-membered heterocyclic ring comprising one or two heteroatoms independently from N, S or O;

A_6 is selected from N, O, S, S(O), $S(O)_2$, CR_6, $C(R_6)_2$, NR_{60}, where R_6 is selected from hydrogen, oxo, fluoro, chloro, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkoxy or (1-2C)haloalkyl and R_{60} is hydrogen, O^-, (1-6C)alkyl, $-C(O)-R_{61}$, $-C(O)O-R_{61}$, or –

$C(O)N(R_{62})R_{61}$, wherein R_{61} is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, aryl, heteroaryl or heterocyclyl and R_{62} is selected from hydrogen or (1-3C)alkyl;

A_7 is selected from N, O, CR_7, S, S(O), $S(O)_2$, $C(R_7)_2$, NR_{70}, where R_{70} is hydrogen, O^-, (1-6C)alkyl, -C(O)-R_{71}, -C(O)O-R_{71} , or $-C(O)N(R_{72})R_{71}$, wherein R_{71} is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, aryl, heteroaryl or heterocyclyl and R_{72} is selected from hydrogen or (1-3C)alkyl;

m is 0, 1 or 2;

R_7 and R_{11} are each independently halo, cyano, oxo, or a group

$$W^2\text{-}X^2\text{-}Y^2\text{-}X^3\text{-}Z^2$$

wherein

W^2 is absent or a linker group of the formula $-[CR^xR^y]_r-$ in which r is an integer selected from 1, 2, 3 or 4, and R^x and R^y are each independently selected from hydrogen or (1-2C)alkyl;

X^2 is absent, -O-, -C(O)-, -C(O)O-, -OC(O)-, -CH(OR^z)-, -N(R^z)-, $-N(R^z)$-C(O)-, -N(R^z)-C(O)O-, -C(O)-N(R^z)-, -N(R^z)C(O)N(R^z)-, -S-, -SO-, $-SO_2$-, $-S(O)_2N(R^z)$-, or $-N(R^z)SO_2$,wherein R^z is selected from hydrogen or methyl;

Y^2 is absent or a linker group of the formula $-[CR^{aa}R^{bb}]_s-$ in which s is an integer selected from 1, 2, 3 or 4, and R^{aa} and R^{bb} are each independently selected from hydrogen or (1-2C)alkyl;

X^3 is absent, -O-, -C(O)-, -C(O)O-, -OC(O)-, -CH(OR^{cc})-, -N(R^{cc})-, $-N(R^{cc})$-C(O)-, $-N(R^{cc})$-C(O)O-, -C(O)-N(R^{cc})-, -N(R^{cc})C(O)N(R^{cc})-, -S-, -SO-, $-SO_2$-, $-S(O)_2N(R^{cc})$-, or $-N(R^{cc})SO_2$,wherein R^{cc} is selected from hydrogen or methyl; and

Z^2 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl, or heterocyclyl,

and wherein Z^2 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, $NR^{dd}R^{ee}$, (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-4C)alkanoyl, (1-4C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, $C(O)NR^{dd}R^{ee}$, $NR^{dd}C(O)R^{ee}$, $NR^{dd}SO_2R^{ee}$ and $SO_2NR^{dd}R^{ee}$; wherein R^{dd} and R^{ee} are each independently selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or R^{dd} and R^{ee} can be linked such that, together

with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z^2 is optionally further substituted by halo, cyano, nitro, hydroxy, carboxy, $NR^{ff}R^{gg}$, (1-2C)alkoxy, or (1-2C)alkyl; wherein R^{ff} and R^{gg} are selected from hydrogen or (1-2C)alkyl;

with the proviso that when R_7 is hydrogen (i.e. when W^2, X^2, Y^2, and X^3 are absent and Z^2 is hydrogen) then ring A is not a fused dioxane ring.

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1, wherein A_1 is CR_1, A_2 is CR_2 and R_1 and R_2 are both hydrogen or one of R_1 and R_2 is fluoro and the other is hydrogen.

3. A compound according to claim 2, wherein R_1 and R_2 are both hydrogen.

4. A compound according to any one of the preceding claims, wherein R_4 is selected from fluoro, chloro, bromo, iodo, CF_3, OCF_3, cyano, NO_2, (1-4C)alkyl, (1-4C)alkoxy, or a group of the formula:

W-X-Y-Z

wherein

W is absent or (1-3C)alkylene;

X is -O- or $-N(R^a)-$, wherein R^a is selected from hydrogen or (1-2C)alkyl;

Y is absent or a (1-3C)alkylene;

Z is hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl;

and wherein any alkylene, alkyl or cycloalkyl group present in a R_4 substituent group is optionally further substituted by one or more substituent groups independently selected from halo, hydroxy, NR^bR^c, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy, and wherein R^b and R^c are each independently selected from hydrogen or methyl.

5. A compound according to any one of the preceding claims, wherein R_4 is selected from fluoro, chloro, bromo, CF_3, cyano, (1-2C)alkyl, or a group of the formula:

W-X-Y-Z

wherein

W is absent or methylene;

X is -O- or $-N(R^a)-$, wherein R^a is selected from hydrogen or (1-2C)alkyl;


Y is absent;

Z is hydrogen or (1-6C)alkyl;

and wherein any alkylene or alkyl group present in a R_4 substituent group is optionally further substituted by one or more substituent groups independently selected from halo, hydroxy, NR^bR^c or (1-2C)alkoxy, and wherein R^b and R^c are each independently selected from hydrogen or methyl.

6. A compound according to any one of the preceding claims, wherein R_4 is selected from fluoro, chloro or (1-2C)alkyl.

7. A compound according to any one of the preceding claims, wherein Q is selected from a group of formula II:



II

wherein

A_{4a} and A_{4b} are each independently selected from N or CR_9, wherein R_9 is selected from hydrogen, halo, cyano, nitro, hydroxy, NR^dR^e, (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl; wherein R^d and R^e are each independently selected from hydrogen or (1-3C)alkyl;

and wherein any (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl group present in a R_9 substituent group is optionally substituted by one or more substiutents selected from halo, cyano, hydroxy, NR^fR^g or (1-3C)alkoxy, wherein R^f and R^g are each independently selected from hydrogen or (1-2C)alkyl;

A_{4c} is N or CR_{10};

R_{10} is selected from hydrogen, halo, amino, cyano, nitro, hydroxy or a group

$$W^1\text{-}X^1\text{-}Y^1\text{-}X^4\text{-}Z^1$$

wherein

W^1 is absent or a linker group of the formula $-[CR^hR^i]_p-$ in which p is an integer selected from 1 or 2, and R^h and R^i are each independently selected from hydrogen or methyl;

X^1 is absent or -O-, -C(O)-, -C(O)O-, -OC(O)-, $-CH(OR^j)-$, $-N(R^j)-$, $-N(R^j)-C(O)-$, $-N(R^j)-C(O)O-$, $-C(O)-N(R^j)-$, -S-, -SO-, $-SO_2-$, $-S(O)_2N(R^j)-$, or $-N(R^j)SO_2-$ wherein R^j is selected from hydrogen or methyl;

Y^1 is absent or a linker group of the formula $-[CR^kR^l]_q-$ in which q is an integer selected from 1, 2, 3 or 4, and R^k and R^l are each independently selected from hydrogen or (1-2C)alkyl;


X^4 is absent or -O-, -C(O)-, -C(O)O-, -OC(O)-, $-CH(OR^j)-$, $-N(R^j)-$, $-N(R^j)-C(O)-$, $-N(R^j)-C(O)O-$, $-C(O)-N(R^j)-$, -S-, -SO-, $-SO_2-$, $-S(O)_2N(R^j)-$, or $-N(R^j)SO_2-$ wherein R^j is selected from hydrogen or methyl; and

Z^1 is (1-6C)alkyl, aryl, heteroaryl or heterocyclyl;

and wherein Z^1 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, hydroxy, carboxy, NR^mR^n, (1-2C)alkoxy, (1-2C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, (1-2C)alkanoyl, (1-2C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, $C(O)NR^mR^n$, $NR^mC(O)R^n$, $NR^mS(O)_2R^n$ and $S(O)_2NR^mR^n$; wherein R^m and R^n are each independently selected from hydrogen or (1-4C)alkyl; or R^m and R^n can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z^1 is optionally further substituted by halo, cyano, hydroxy, NR^oR^p, (1-2C)alkoxy, or (1-2C)alkyl; wherein R^o and R^p are selected from hydrogen or (1-2C)alkyl;

or Q is a group of formula III:



III

wherein

A_5 is selected from N or CR_5, where R_5 is selected from hydrogen, halo, cyano, hydroxy, NR^qR^u, (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl; wherein R^q and R^u are each independently selected from hydrogen or (1-3C)alkyl;

and wherein any (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteraryl, or 5 or 6 membered heterocyclyl group present in a R_5 substituent group is optionally substituted by one or more substitutents selected from halo, cyano, nitro, hydroxy, NR^vR^w, or (1-3C)alkoxy, wherein R^v and R^w are each independently selected from hydrogen or (1-3C)alkyl;

Ring A is:

a fused phenyl ring;

a fused 5 or 6 membered carbocyclic ring;

a fused 5 or 6 membered heteroaryl ring comprising one or two heteroatoms independently from N, S or O; or

a fused 5, 6 or 7-membered heterocyclic ring comprising one or two heteroatoms independently from N, S or O;

A_6 is selected from N, O, S, $S(O)_2$, CR_6, $C(R_6)_2$, NR_{60}, where R_6 is selected from hydrogen, oxo, fluoro, chloro, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkoxy or (1-2C)haloalkyl and R_{60} is hydrogen, O^-, (1-6C)alkyl, -$C(O)$-R_{61}, -$C(O)O$-R_{61} , or –$C(O)N(R_{62})R_{61}$, wherein R_{61} is selected from hydrogen, (1-6C)alkyl, aryl, heteroaryl or heterocyclyl and R_{62} is selected from hydrogen or (1-2C)alkyl;

A_7 is selected from N, O, CR_7, S, $S(O)_2$, $C(R_7)_2$, NR_{70}, where R_{70} is hydrogen, O^-, (1-6C)alkyl, -$C(O)$-R_{71}, -$C(O)O$-R_{71} , or –$C(O)N(R_{72})R_{71}$, wherein R_{71} is selected from hydrogen, (1-6C)alkyl, aryl, heteroaryl or heterocyclyl and R_{72} is selected from hydrogen or (1-2C)alkyl;

m is 0, 1 or 2;

R_7 and R_{11} are each independently halo, cyano, oxo, or a group

$$W^2\text{-}X^2\text{-}Y^2\text{-}X^3\text{-}Z^2$$

wherein

W^2 is absent or a linker group of the formula $–[CR^xR^y]_r$- in which r is an integer selected from 1, 2, 3 or 4, and R^x and R^y are each independently selected from hydrogen or (1-2C)alkyl;

X^2 is absent, -O-, -$C(O)$-, -$C(O)O$-, -$OC(O)$-, -$CH(OR^z)$-, -$N(R^z)$-, –$N(R^z)$-$C(O)$-, -$N(R^z)$-$C(O)O$-, -$C(O)$-$N(R^z)$-, -S-, -SO-, -SO_2-, -$S(O)_2N(R^z)$-, or -$N(R^z)SO_2$, wherein R^z is selected from hydrogen or methyl;

Y^2 is absent or a linker group of the formula $–[CR^{aa}R^{bb}]_s$- in which s is an integer selected from 1, 2, 3 or 4, and R^{aa} and R^{bb} are each independently selected from hydrogen or (1-2C)alkyl;

X^3 is absent, -O-, -$C(O)$-, -$C(O)O$-, -$OC(O)$-, -$CH(OR^{cc})$-, -$N(R^{cc})$-, –$N(R^{cc})$-$C(O)$-, –$N(R^{cc})$-$C(O)O$-, -$C(O)$-$N(R^{cc})$-, -S-, -SO-, -SO_2-, -$S(O)_2N(R^{cc})$-, or -$N(R^{cc})SO_2$,wherein R^{cc} is selected from hydrogen or methyl; and


Z^2 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, aryl, (3-6C)cycloalkyl, heteroaryl, or heterocyclyl,

and wherein Z^2 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro,


hydroxy, carboxy, $NR^{dd}R^{ee}$, (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (1-2C)alkanoyl, (1-2C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, $C(O)NR^{dd}R^{ee}$, $NR^{dd}C(O)R^{ee}$, $NR^{dd}SO_2R^{ee}$ and $SO_2NR^{dd}R^{ee}$; wherein R^{dd} and R^{ee} are each independently selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl; or R^{dd} and R^{ee} can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z^2 is optionally further substituted by halo, cyano, nitro, hydroxy, carboxy, $NR^{ff}R^{gg}$, (1-2C)alkoxy, or (1-2C)alkyl; wherein R^{ff} and R^{gg} are selected from hydrogen or (1-2C)alkyl;


8. A compound according to any one of the preceding claims, wherein Q has one of the structural formulae IIa, IIb, IIc, IId, IIe, IIIa and IIIb shown below:




IIa




IIb




IIc




IId



IIe



IIIa



IIIb

wherein R_9, R_{10}, A_5, A_6, A_7, R_{11} and m each have any one of the defintions hereinbefore;

ring A1 is a fused 5-membered carbocyclic ring, 5-membered heterocyclic ring or 5-membered heteroaryl ring;

ring A2 is a fused 6 or 7-membered carbocyclic ring, 6 or 7-membered heterocyclic ring or 6-membered heteroaryl ring.

9. A compound according to claim 8, wherein Q is a group of formula IIa, IIb, IIc, IId or IIe.

10. A compound according to any one of the preceding claims, wherein A_{4a} and A_{4b} are each independently selected from N or CR_9, wherein R_9 is selected from hydrogen, halo, cyano, hydroxy, NR^dR^e, (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl; wherein R^d and R^e are each independently selected from hydrogen or (1-2C)alkyl, and A_{4c} is N or CR_{10},

wherein R_{10} is selected from hydrogen, halo, amino, cyano, hydroxy or a group

$$W^1\text{-}X^1\text{-}Y^1\text{-}X^4\text{-}Z^1$$

wherein

W^1 is absent or a linker group of the formula $-[CR^hR^i]_p-$ in which p is an integer selected from 1 or 2, and R^h and R^i are hydrogen;

X^1 is absent or -O-, -C(O)-, -C(O)O-, -OC(O)-, $-N(R^j)-$, $-N(R^j)$-C(O)-, $-N(R^j)$-C(O)O-, -C(O)-$N(R^j)$-, -S-, -SO-, $-SO_2-$, $-S(O)_2N(R^j)-$, or $-N(R^j)SO_2-$ wherein R^j is selected from hydrogen or methyl;

Y^1 is absent or a linker group of the formula $-[CR^kR^l]_q-$ in which q is an integer selected from 1, 2, 3 or 4, and R^k and R^l are each independently selected from hydrogen or methyl;

X^4 is absent or -O-, -C(O)-, -C(O)O-, -OC(O)-, $-N(R^j)-$, $-N(R^j)$-C(O)-, $-N(R^j)$-C(O)O-, -C(O)-$N(R^j)$-, -S-, -SO-, $-SO_2-$, $-S(O)_2N(R^j)-$, or $-N(R^j)SO_2-$ wherein R^j is selected from hydrogen or methyl; and

Z^1 is (1-6C)alkyl, aryl, heteroaryl or heterocyclyl;

and wherein Z^1 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, hydroxy, carboxy, NR^mR^n, (1-2C)alkoxy, (1-2C)alkyl, (3-6C)cycloalkyl, (1-2C)alkanoyl, (1-2C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy,

heteroaryl-(1-2C)alkyl, $C(O)NR^mR^n$, $NR^mC(O)R^n$, $NR^mS(O)_2R^n$ and $S(O)_2NR^mR^n$; wherein R^m and R^n are each independently selected from hydrogen or (1-4C)alkyl; or R^m and R^n can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z^1 is optionally further substituted by halo, cyano, hydroxy, NR^oR^p, (1-2C)alkoxy, or (1-2C)alkyl; wherein R^o and R^p are selected from hydrogen or (1-2C)alkyl;

11. A compound according to any one of the preceding claims, wherein R_{10} is selected from hydrogen, halo, amino, cyano, hydroxy or a group

$$W^1\text{-}X^1\text{-}Y^1\text{-}X^4\text{-}Z^1$$

wherein

W^1 is absent;

X^1 is absent or -O-, -C(O)-, -C(O)O-, -OC(O)-, $-N(R^j)$-, $-N(R^j)$-C(O)-, $-N(R^j)$-C(O)O-, -C(O)-$N(R^j)$-, -S-, -SO-, $-SO_2$-, $-S(O)_2N(R^j)$-, or $-N(R^j)SO_2$- wherein R^j is selected from hydrogen or methyl;

Y^1 is absent or a linker group of the formula $-[CR^kR^l]_q$- in which q is an integer selected from 1, 2, 3 or 4, and R^k and R^l are hydrogen;

X^4 is absent or -O-, -C(O)-, -C(O)O-, -OC(O)-, $-N(R^j)$-, $-N(R^j)$-C(O)-, $-N(R^j)$-C(O)O-, -C(O)-$N(R^j)$-, -S-, -SO-, $-SO_2$-, $-S(O)_2N(R^j)$-, or $-N(R^j)SO_2$- wherein R^j is selected from hydrogen or methyl; and

Z^1 is (1-6C)alkyl, aryl, heteroaryl or heterocyclyl;

and wherein Z^1 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, hydroxy, NR^mR^n, (1-2C)alkoxy, (1-2C)alkyl, (3-6C)cycloalkyl, (1-2C)alkanoyl, (1-2C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, $C(O)NR^mR^n$, $NR^mC(O)R^n$, $NR^mS(O)_2R^n$ and $S(O)_2NR^mR^n$; wherein R^m and R^n are each independently selected from hydrogen or (1-4C)alkyl; or R^m and R^n can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z^1 is optionally further substituted by

halo, cyano, hydroxy, NR^oR^p, (1-2C)alkoxy, or (1-2C)alkyl; wherein R^o and R^p are selected from hydrogen or (1-2C)alkyl;

12. A compound according to any one of the preceding claims, wherein A_{4a} and A_{4b} are CR_9 and A_{4c} is CR_{10}, or one or two of A_{4a}, A_{4b} and A_{4c} are N and the others are CR_9 (in the case of A_{4a} and A_{4b}) or CR_{10} (in the case of A_{4c}).

13. A compound according to claim 8, wherein Q is of formula IIIa or IIIb.

14. A compound according to any one of the preceding claims, wherein A_5 is selected from N or CR_5, where R_5 is selected from hydrogen, halo, cyano, hydroxy, NR^qR^u, (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl; wherein R^q and R^u are each independently selected from hydrogen or (1-3C)alkyl; and wherein any (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteraryl, or 5 or 6 membered heterocyclyl group present in a R_5 substituent group is optionally substituted by one or more substitutents selected from halo, cyano, hydroxy, NR^vR^w, or (1-3C)alkoxy, wherein R^v and R^w are each independently selected from hydrogen or (1-3C)alkyl;

15. A compound according to any one of the preceding claims, wherein Ring A is:

a fused 5 or 6 membered heteroaryl ring comprising one or two heteroatoms independently from N, S or O; or

a fused 5, 6 or 7-membered heterocyclic ring comprising one or two heteroatoms independently from N, S or O.

16. A compound according to any one of the preceding claims, wherein A_6 is selected from N, O, S, $S(O)_2$, CR_6, $C(R_6)_2$, NR_{60},

where R_6 is selected from hydrogen, oxo, fluoro, chloro, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkoxy or (1-2C)haloalkyl; and

R_{60} is hydrogen, O^-, (1-6C)alkyl, $-C(O)-R_{61}$, $-C(O)O-R_{61}$, or $-C(O)N(R_{62})R_{61}$, wherein R_{61} is selected from hydrogen, (1-6C)alkyl, aryl, 5 or 6 membered heteroaryl or 5 or 6 membered heterocyclyl and R_{62} is selected from hydrogen or (1-2C)alkyl.

17. A compound according to any one of the preceding claims, wherein A_7 is selected from N, O, CR_7, S, $S(O)_2$, $C(R_7)_2$, NR_{70}, where R_{70} is hydrogen, O^-, (1-6C)alkyl, -C(O)-R_{71}, -C(O)O-R_{71} , or –C(O)N(R_{72})R_{71} , wherein R_{71} is selected from hydrogen, (1-6C)alkyl, aryl, 5 or 6 membered heteroaryl or 5 or 6 membered heterocyclyl and R_{72} is selected from hydrogen or (1-2C)alkyl;

R_7 is selected from halo, cyano, oxo, or a group

$$W^2\text{-}X^2\text{-}Y^2\text{-}X^3\text{-}Z^2$$

wherein

W^2 is absent or a linker group of the formula $–[CR^xR^y]_r$- in which r is an integer selected from 1, 2, or 3, and R^x and R^y are each independently selected from hydrogen or (1-2C)alkyl;

X^2 is absent, -O-, -C(O)-, -C(O)O-, -OC(O)-, -N(R^z)-, –N(R^z)-C(O)-, -N(R^z)-C(O)O-, -C(O)-N(R^z)-, -S-, -SO-, -SO_2-, -$S(O)_2$N(R^z)-, or -N(R^z)SO_2, wherein R^z is selected from hydrogen or methyl;

Y^2 is absent or a linker group of the formula $–[CR^{aa}R^{bb}]_s$- in which s is an integer selected from 1, 2, 3 or 4, and R^{aa} and R^{bb} are each independently selected from hydrogen or (1-2C)alkyl;

X^3 is absent, -O-, -C(O)-, -C(O)O-, -OC(O)-, -N(R^{cc})-, –N(R^{cc})-C(O)-, –N(R^{cc})-C(O)O-, -C(O)-N(R^{cc})-, -S-, -SO-, -SO_2-, -$S(O)_2$N(R^{cc})-, or -N(R^{cc})SO_2,wherein R^{cc} is selected from hydrogen or methyl; and

Z^2 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, aryl, (3-6C)cycloalkyl, heteroaryl, or heterocyclyl,

and wherein Z^2 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, hydroxy, carboxy, $NR^{dd}R^{ee}$, (1-4C)alkoxy, (1-4C)alkyl, (1-2C)alkanoyl, (1-2C)alkylsulphonyl, C(O)$NR^{dd}R^{ee}$, $NR^{dd}C(O)R^{ee}$, $NR^{dd}SO_2R^{ee}$ and $SO_2NR^{dd}R^{ee}$; wherein R^{dd} and R^{ee} are each independently selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl; or R^{dd} and R^{ee} can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z^2 is optionally further substituted by halo, cyano, nitro, hydroxy, carboxy, $NR^{ff}R^{gg}$, (1-2C)alkoxy, or (1-2C)alkyl; wherein R^{ff} and R^{gg} are selected from hydrogen or (1-2C)alkyl;

18. A compound according to any one of the preceding claims, wherein R_7 is selected from halo, cyano, oxo, or a group

W^2-X^2-Y^2-X^3-Z^2

wherein

W^2 is absent or a linker group of the formula $–[CR^xR^y]_r$- in which r is an integer selected from 1, 2, or 3, and R^x and R^y are each independently selected from hydrogen or (1-2C)alkyl;

X^2 is absent, -O-, -C(O)-, -C(O)O-, -OC(O)-, -N(R^z)-, –N(R^z)-C(O)-, -N(R^z)-C(O)O-, -C(O)-N(R^z)-, -S-, -SO-, -SO_2-, -$S(O)_2N(R^z)$-, or -N(R^z)SO_2, wherein R^z is selected from hydrogen or methyl;

Y^2 is absent or a linker group of the formula $–[CR^{aa}R^{bb}]_s$- in which s is an integer selected from 1, 2, 3 or 4, and R^{aa} and R^{bb} are each independently selected from hydrogen or (1-2C)alkyl;

X^3 is absent, -O-, -C(O)-, -C(O)O-, -OC(O)-, -N(R^{cc})-, –N(R^{cc})-C(O)-, –N(R^{cc})-C(O)O-, -C(O)-N(R^{cc})-, -S-, -SO-, -SO_2-, -$S(O)_2N(R^{cc})$-, or -N(R^{cc})SO_2,wherein R^{cc} is selected from hydrogen or methyl; and

Z^2 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, phenyl, (3-6C)cycloalkyl, 5 or 6 membered heteroaryl, or 5 or 6 membered heterocyclyl,

and wherein Z^2 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, hydroxy, carboxy, $NR^{dd}R^{ee}$, (1-4C)alkoxy, (1-4C)alkyl, (1-2C)alkanoyl, (1-2C)alkylsulphonyl, $C(O)NR^{dd}R^{ee}$, $NR^{dd}C(O)R^{ee}$, $NR^{dd}SO_2R^{ee}$ and $SO_2NR^{dd}R^{ee}$; wherein R^{dd} and R^{ee} are each independently selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl; or R^{dd} and R^{ee} can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

19. A compound according to any one of the preceding claims, wherein m is 0 or 1.

20. A compound according to any one of the preceding claims, wherein R_{11} is selected from halo, cyano, oxo, or a group

W^2-X^2-Y^2-X^3-Z^2

wherein

W^2 is absent or a linker group of the formula $–[CR^xR^y]_r$- in which r is an integer selected from 1, 2, or 3, and R^x and R^y are each independently selected from hydrogen or (1-2C)alkyl;

X^2 is absent, -O-, -C(O)-, -C(O)O-, -OC(O)-, -N(R^z)-, –N(R^z)-C(O)-, -N(R^z)-C(O)O-, -C(O)-N(R^z)-, -S-, -SO-, -SO_2-, -$S(O)_2N(R^z)$-, or -N(R^z)SO_2, wherein R^z is selected from hydrogen or methyl;

Y^2 is absent or a linker group of the formula $-[CR^{aa}R^{bb}]_s-$ in which s is an integer selected from 1, 2, 3 or 4, and R^{aa} and R^{bb} are each independently selected from hydrogen or (1-2C)alkyl;


X^3 is absent, -O-, -C(O)-, -C(O)O-, -OC(O)-, $-N(R^{cc})-$, $-N(R^{cc})$-C(O)-, $-N(R^{cc})$-C(O)O-, -C(O)-$N(R^{cc})$-, -S-, -SO-, $-SO_2-$, $-S(O)_2N(R^{cc})-$, or $-N(R^{cc})SO_2$,wherein R^{cc} is selected from hydrogen or methyl; and

Z^2 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, aryl, (3-6C)cycloalkyl, heteroaryl, or heterocyclyl,

and wherein Z^2 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, hydroxy, carboxy, $NR^{dd}R^{ee}$, (1-4C)alkoxy, (1-4C)alkyl, (1-2C)alkanoyl, (1-2C)alkylsulphonyl, $C(O)NR^{dd}R^{ee}$, $NR^{dd}C(O)R^{ee}$, $NR^{dd}SO_2R^{ee}$ and $SO_2NR^{dd}R^{ee}$; wherein R^{dd} and R^{ee} are each independently selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl; or R^{dd} and R^{ee} can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z^2 is optionally further substituted by halo, cyano, nitro, hydroxy, carboxy, $NR^{ff}R^{gg}$, (1-2C)alkoxy, or (1-2C)alkyl; wherein R^{ff} and R^{gg} are selected from hydrogen or (1-2C)alkyl;

21. A compound according to any one of the preceding claims, wherein Q is a group of formula:



wherein R_7 is a group

$$W^2\text{-}X^2\text{-}Y^2\text{-}X^3\text{-}Z^2$$

wherein

W^2 is a linker group of the formula $-[CR^xR^y]_r-$ in which r is 1, R^x is hydrogen and R^y is selected from hydrogen or methyl;

X^2 is absent;

Y^2 is absent;

X^3 is absent; and

Z^2 is a 4, 5, 6 or 7-membered nitrogen-linked heterocyclyl optionally comprising one further nitrogen atom,
and wherein Z^2 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, hydroxy, carboxy, $NR^{dd}R^{ee}$, (1-4C)alkoxy, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, (2C)alkanoyl, (1-2C)alkylsulphonyl, $C(O)NR^{dd}R^{ee}$, $NR^{dd}C(O)R^{ee}$, $NR^{dd}SO_2R^{ee}$ and $SO_2NR^{dd}R^{ee}$; wherein R^{dd} and R^{ee} are each independently selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl;

22. A compound according to any one of the preceding claims, which is selected from any one of the following:
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)isoquinoline-7-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-methoxyethoxy)quinoline-6-carboxamide;
N-(4-methyl-3-(2-oxo-2H-chromene-6-carboxamido)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N-(3-(3,4-dimethoxybenzamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N-(3-(2,3-dihydrobenzofuran-5-carboxamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1-methylindoline-5-carboxamide;
N-(4-methyl-3-(1-oxo-1,3-dihydroisobenzofuran-5-carboxamido)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N-(3-(chroman-6-carboxamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinazoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-4-methoxyquinoline-6-carboxamide;
2-chloro-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-(thiazol-4-ylmethoxy)nicotinamide;

N-(4-methyl-3-(2-methyl-2,3-dihydrobenzofuran-5-carboxamido)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

N-(3-(1,3-dihydroisobenzofuran-5-carboxamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1-methyl-1H-indole-5-carboxamide;

N-(3-(benzofuran-5-carboxamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

N-(3-(benzo[b]thiophene-5-carboxamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

N-(4-methyl-3-(4-(pyridin-2-ylmethoxy)benzamido)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

N-(4-methyl-3-(4-(thiazol-5-ylmethoxy)benzamido)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

tert-butyl (2-((6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)quinolin-2-yl)oxy)ethyl)carbamate;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-4-methoxy-2-(2-methoxyethoxy)quinoline-6-carboxamide;

6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)quinoline 1-oxide;

4-cyano-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-(pyridin-2-ylmethoxy)nicotinamide;

N-(3-(4-methoxy-3-methylbenzamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

N-(3-(4-methoxybenzamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

N-(3-(3-chloro-4-methoxybenzamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methoxyquinoline-6-carboxamide;

tert-butyl 5-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)indoline-1-carboxylate;

tert-butyl 6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-morpholinoquinoline-6-carboxamide;
N5-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-N2-methylpyridine-2,5-dicarboxamide;
N-(4-methyl-3-(5,6,7,8-tetrahydronaphthalene-2-carboxamido)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
tert-butyl (3-((6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)quinolin-2-yl)oxy)propyl)carbamate;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoxaline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-phenylnicotinamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-((3-iodophenyl)amino)nicotinamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide;
N-(3-(3-methoxybenzamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N-(3-(4-bromo-3-methoxybenzamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N-(3-(4-methoxy-3,5-dimethylbenzamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1,6-naphthyridine-3-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1,7-naphthyridine-3-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1,8-naphthyridine-3-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)isoquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-3-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-oxo-1,2-dihydroquinoline-6-carboxamide;

(R)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((1-methylpyrrolidin-3-yl)oxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((1-methylpiperidin-4-yl)oxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-(dimethylamino)propoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-(piperidin-1-yl)propoxy)quinoline-6-carboxamide;
(S)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((1-methylpyrrolidin-2-yl)methoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(piperidin-1-yl)ethoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-morpholinopropoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-(pyrrolidin-1-yl)propoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(3-fluoropiperidin-1-yl)ethoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((2-(dimethylamino)ethyl)(methyl)amino)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(pyrrolidin-1-yl)ethyl)quinoline-6-carboxamide;
2-(2-(azetidin-1-yl)ethoxy)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(2-methylpyrrolidin-1-yl)ethoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(dimethylamino)ethoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(pyrrolidin-1-yl)ethoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(methyl(2-(pyrrolidin-1-yl)ethyl)amino)quinoline-6-carboxamide;
(S)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(3-fluoropyrrolidin-1-yl)ethoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-morpholinoethoxy)quinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(pyrrolidin-1-ylmethyl)quinoline-6-carboxamide formate;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(pyrrolidin-1-yl)propoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(dimethylamino)ethyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((4-methylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((dimethylamino)methyl)quinoline-6-carboxamide;
2-(2-(4,4-difluoropiperidin-1-yl)ethoxy)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((1-(pyrrolidin-1-yl)propan-2-yl)oxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(4-methylpiperazin-1-yl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-hydroxyethyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-(methylamino)propoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-ethylquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((N-methylpropionamido)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(methylamino)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1,2,3,4-tetrahydroquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-propionamidoethoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-7-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((2-propionamidoethyl)amino)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)indoline-5-carboxamide;

tert-butyl ((6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)-1,2,3,4-tetrahydroquinolin-2-yl)methyl)(methyl)carbamate;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((methylamino)methyl)-1,2,3,4-tetrahydroquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((dimethylamino)methyl)-1,2,3,4-tetrahydroquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide;
2-(2-aminoethoxy)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-6-carboxamide;
2-amino-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)benzo[d]thiazole-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-3H-imidazo[4,5-b]pyridine-6-carboxamide;
N-(3-(4-hydroxybenzamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-(phenylamino)nicotinamide;
2-amino-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-4-methoxybenzo[d]thiazole-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(1H-1,2,4-triazol-1-yl)isonicotinamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1H-indazole-5-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-morpholinoisonicotinamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide;
N-(4-methyl-3-(4-(thiazol-4-ylmethoxy)benzamido)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-(ethylamino)nicotinamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-oxo-1,2,3,4-tetrahydroquinoline-6-carboxamide;

6-amino-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)nicotinamide;

2-amino-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)isonicotinamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-(1H-pyrazol-1-yl)nicotinamide;

N-(3-(4-(1H-pyrazol-1-yl)benzamido)-4-methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

N-(4-methyl-3-(6-methyl-2-naphthamido)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-3-methyl-4-oxo-3,4-dihydroquinazoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-4-(2-(dimethylamino)ethylamino)-2-methylquinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-4-(3-(dimethylamino)propylamino)-2-methylquinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methyl-4-(methyl(1-methylpyrrolidin-3-yl)amino)quinoline-6-carboxamide;

N-(3-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-methylquinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)benzo[d]thiazole-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(methylamino)benzo[d]thiazole-6-carboxamide;

2-amino-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)benzo[d]thiazole-7-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methyl-4-(2-(pyrrolidin-1-yl)ethylamino)quinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methyl-4-(2-morpholinoethylamino)quinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methylquinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)quinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-(3-(1-methylpiperidin-4-yloxy)phenylamino)nicotinamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-(3-(4-methylpiperazin-1-yl)propylamino)nicotinamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-(3-((4-methylpiperazin-1-yl)methyl)phenylamino)nicotinamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-(3-((dimethylamino)methyl)phenylamino)nicotinamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-6-(3-(3-(dimethylamino)pyrrolidin-1-yl)phenylamino)nicotinamide;
N-(3-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-methylquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-(trifluoromethyl)phenyl)-2-methylquinoline-6-carboxamide;
N-(5-(7-fluoro-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide;
N-(5-(benzo[d][1,3]dioxole-5-carboxamido)-2-methylphenyl)quinoline-6-carboxamide;
N-(5-(3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-carboxamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-ethylphenyl)quinoline-6-carboxamide;
N-(4-methyl-3-(2-(2-(pyrrolidin-1-yl)ethoxy)quinoline-6-carboxamido)phenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-7-carboxamide;
N-(4-methyl-3-(2-methylquinoline-6-carboxamido)phenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-7-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-8-fluoroquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(methoxymethyl)quinoline-6-carboxamide;
N-(2-bromo-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)quinoline-6-carboxamide;
N-(2-bromo-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-(2-(pyrrolidin-1-yl)ethoxy)quinoline-6-carboxamide;

N-(2-cyano-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-5,6,7,8-tetrahydroquinoline-3-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(1-hydroxyethyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-morpholinoethyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(isopropoxymethyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(((tetrahydrofuran-2-yl)methoxy)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((2-(pyrrolidin-1-yl)ethoxy)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)quinoline-3-carboxamide;
N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-3-((2-methoxyethyl)amino)-2-(2-(pyrrolidin-1-yl)ethoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(isobutoxymethyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(1-methoxyethyl)quinoline-6-carboxamide;
(S)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide;
(R)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-3-(2-(pyrrolidin-1-yl)ethoxy)isoquinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-5-(2-hydroxyethyl)quinoline-3-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-5-(2-(pyrrolidin-1-yl)ethyl)quinoline-3-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1,2-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-8-(2-methoxyethoxy)quinoline-6-carboxamide;

5-allyl-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-3-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-8-((2-(dimethylamino)ethyl)(methyl)amino)quinoline-6-carboxamide;

3-((6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)quinolin-2-yl)(methyl)amino)propanoic acid;

tert-butyl (4-((6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)quinolin-2-yl)oxy)butyl)carbamate;

N-(5-(2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-(dimethylamino)methyl)phenyl)-2-methylquinoline-6-carboxamide

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-(methoxymethyl)phenyl)-2-methylquinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-(hydroxymethyl)phenyl)-2-methylquinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1-methyl-1,3-dihydrobenzo[c]isothiazole-5-carboxamide 2,2-dioxide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-(pyrrolidin-1-ylmethyl)quinoline-6-carboxamide;

2-(azetidin-1-ylmethyl)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)quinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-(piperidin-1-ylmethyl)quinoline-6-carboxamide

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-methylpiperazin-1-yl)methyl)quinoline-6-carboxamide;

N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-(piperazin-1-ylmethyl)quinoline-6-carboxamide;

(S)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((2-methylpyrrolidin-1-yl)methyl)quinoline-6-carboxamide;

(R)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((2-methylpyrrolidin-1-yl)methyl)quinoline-6-carboxamide;
2-((4-(tert-butyl)piperazin-1-yl)methyl)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)quinoline-6-carboxamide;
2-((4-cyclopropylpiperazin-1-yl)methyl)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)quinoline-6-carboxamide;
2-((4-(sec-butyl)piperazin-1-yl)methyl)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-(((1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)quinoline-6-carboxamide;
2-(2-azaspiro[3.3]heptan-2-ylmethyl)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((3-methylazetidin-1-yl)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((3,3-dimethylazetidin-1-yl)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethyl-1,4-diazepan-1-yl)methyl)quinoline-6-carboxamidel
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-isopropylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-(3-(piperidin-1-yl)propoxy)quinoline-6-carboxamide
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-(3-(pyrrolidin-1-yl)propoxy)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-(2-(pyrrolidin-1-yl)ethoxy)quinoline-6-carboxamide;
N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-(3-(piperidin-1-yl)propoxy)quinoline-6-carboxamide;
(rac)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((2-methylpyrrolidin-1-yl)methyl)quinoline-6-carboxamide;
2-((4-(tert-butyl)piperazin-1-yl)methyl)-N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)quinoline-6-carboxamide;
N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-(piperazin-1-ylmethyl)quinoline-6-carboxamide;
2-((4-(sec-butyl)piperazin-1-yl)methyl)-N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)quinoline-6-carboxamide;

N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-((4-cyclopropylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-((4-methylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-((4-isopropylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-(pyrrolidin-1-ylmethyl)quinoline-6-carboxamide
2-(azetidin-1-ylmethyl)-N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)quinoline-6-carboxamide;
N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-((3-methylazetidin-1-yl)methyl)quinoline-6-carboxamide;
N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-((3,3-dimethylazetidin-1-yl)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((4-isopropylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
2-(azetidin-1-ylmethyl)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((2-methylpyrrolidin-1-yl)methyl)quinoline-6-carboxamide;
(R)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((3-fluoropyrrolidin-1-yl)methyl)quinoline-6-carboxamide;
(S)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((3-fluoropyrrolidin-1-yl)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-((3-methoxypyrrolidin-1-yl)methyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(piperidin-1-ylmethyl)quinoline-6-carboxamide;
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-vinylphenyl)-2-methylquinoline-6-carboxamide;
N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-(2-(pyrrolidin-1-yl)ethoxy)quinoline-6-carboxamide;

(R)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethyl-2-methylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
(S)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethyl-2-methylpiperazin-1-yl)methyl)quinoline-6-carboxamide
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-(1-(4-ethylpiperazin-1-yl)ethyl)quinoline-6-carboxamide;
N-(2-bromo-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
2-(azetidin-1-ylmethyl)-N-(2-bromo-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)quinoline-6-carboxamide;
(S)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-isopropyl-2-methylpiperazin-1-yl)methyl)quinoline-6-carboxamide
(R)-N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-isopropyl-2-methylpiperazin-1-yl)methyl)quinoline-6-carboxamide;
or a pharmaceutically acceptable salt or solvate thereof.

23. A pharmaceutical composition comprising a compound according to claims 1 to 22, or a pharmaceutically acceptable salt or solvate thereof, in admixture with a pharmaceutically acceptable diluent or carrier.

24. A compound as defined in any one of claims 1 to 22, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.

25. A compound as defined in any one of claims 1 to 22, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of cancer, autoimmune diseases or viral diseases.

26. A compound as defined in any one of claims 1 to 22, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of cancer.

27. Use of a therapeutically effective amount of a compound according to claims 1 to 22, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating cancer, autoimmune diseases or viral diseases in a patient in need of such treatment.

28. The use of claim 27, wherein the condition is cancer.